VICTORIA, Oct. 1, 2019 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB:
IPATF) a provider of best-in-class therapeutic antibody discovery
capabilities for the global industry, today announced the
appointment of industry professional and leader, Dr. Stefan Lang, as Chief Business Officer. In
this newly created role, Dr. Lang, who has more than 20 years of
experience as a senior executive in the biotechnology industry,
will be responsible for corporate and business development
initiatives, as well as corporate and product strategic
planning.
![ImmunoPrecise Antibodies Ltd. (CNW Group/ImmunoPrecise Antibodies Ltd.) ImmunoPrecise Antibodies Ltd. (CNW Group/ImmunoPrecise Antibodies Ltd.)](https://mma.prnewswire.com/media/1004069/ImmunoPrecise_Antibodies_Ltd__ImmunoPrecise_Antibodies_Appoints.jpg)
"We are excited to welcome Dr. Lang to ImmunoPrecise. He brings
an impressive breadth of leadership expertise in the biotech
industry, including experience working at the organizational level
and as a globally-recognized and respected leader in antibody
business development" said Dr. Jennifer
Bath, Chief Executive Officer of ImmunoPrecise. "We look
forward to Dr. Lang's insightful contributions as we pursue our
mission of transforming next generation antibody therapeutics and
diagnostics."
Dr. Lang joins ImmunoPrecise from Aldevron LLC, where he served
as the Vice President of Business Development. He brings extensive
background knowledge in the therapeutic antibody sector including
corporate strategy, R&D innovation, sales and business
development. He holds a Dr. rer. nat. in biology from the technical
university of Karlsruhe, Germany.
"I am thrilled to join ImmunoPrecise Antibodies at such an
exciting time in the Company's development," said Dr. Lang. "In
only a few years, ImmunoPrecise has established itself as a leader
in the antibody discovery space, with a clear vision and the
technical capabilities to become the preferred partner of choice
for this industry. I see tremendous opportunity to build on this
progress and I am eager to lend my expertise to ImmunoPrecise as
the partner-of-choice for biopharmaceutical companies pursuing
antibody discovery in immunotherapies and diagnostics. I look
forward to leveraging my extensive business development and
commercial experience to support the Company's strategic plan."
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is an international, full-service, therapeutic
antibody discovery company offering species agnostic advancements
such as the B cell SelectTM single-cell technology and
the DeepDisplayTM custom phage libraries, as well as the
AbthenaTM bispecific program. All of these technologies
integrate seamlessly with IPA's
integrated ArtemisTM Intelligence Metadata
(AIM)TM capabilities to enable rapid turnaround on
additional outputs in therapeutic optimization, stability,
affinity, and manufacturability.
ImmunoPrecise discovery and development are conducted in
Utrecht and Oss, the Netherlands (U-Protein Express and IPA
Europe, respectively), and in Victoria,
British Columbia (IPA Canada). The Company operates globally
to offer a continuum of superior antibody services, transforming
the face of therapeutic discovery, by decreasing turnaround time
and risk, and promoting clinical success.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal year ended April 30,
2018 which can be accessed at www.sedar.com. The
"forward-looking statements" contained herein speak only as of the
date of this press release and, unless required by applicable law,
ImmunoPrecise undertakes no obligation to publicly update or revise
such information, whether as a result of new information, future
events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.